

HOUSE BILL 15

C3, J1

9lr0803

(PRE-FILED)

By: **Delegate Sydnor**

Requested: November 20, 2018

Introduced and read first time: January 9, 2019

Assigned to: Health and Government Operations

A BILL ENTITLED

1 AN ACT concerning

2 **Health Insurance – Pediatric Autoimmune Neuropsychiatric Disorders –**
3 **Coverage**

4 FOR the purpose of requiring the Maryland Medical Assistance Program, beginning on a
5 certain date, to provide services for pediatric autoimmune neuropsychiatric
6 disorders associated with streptococcal infections and pediatric acute onset
7 neuropsychiatric syndrome under certain circumstances; requiring insurers,
8 nonprofit health service plans, and health maintenance organizations that provide
9 certain health insurance benefits under certain insurance policies or contracts to
10 provide coverage for certain diagnosis, evaluation, and treatment of pediatric
11 autoimmune neuropsychiatric disorders associated with streptococcal infections and
12 pediatric acute onset neuropsychiatric syndrome; providing that the required
13 coverage may be subject to certain deductibles, copayments, and coinsurance;
14 providing for the application of this Act; providing for a delayed effective date; and
15 generally relating to coverage for pediatric autoimmune neuropsychiatric disorder
16 and pediatric acute onset neuropsychiatric syndrome diagnosis, evaluation, and
17 treatment under health insurance.

18 BY repealing and reenacting, without amendments,
19 Article – Health – General
20 Section 15–103(a)(1)
21 Annotated Code of Maryland
22 (2015 Replacement Volume and 2018 Supplement)

23 BY repealing and reenacting, with amendments,
24 Article – Health – General
25 Section 15–103(a)(2)(xii) and (xiii)
26 Annotated Code of Maryland
27 (2015 Replacement Volume and 2018 Supplement)

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 BY adding to
2 Article – Health – General
3 Section 15–103(a)(2)(xiv)
4 Annotated Code of Maryland
5 (2015 Replacement Volume and 2018 Supplement)

6 BY adding to
7 Article – Insurance
8 Section 15–854
9 Annotated Code of Maryland
10 (2017 Replacement Volume and 2018 Supplement)

11 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
12 That the Laws of Maryland read as follows:

13 **Article – Health – General**

14 15–103.

15 (a) (1) The Secretary shall administer the Maryland Medical Assistance
16 Program.

17 (2) The Program:

18 (xii) Shall provide services in accordance with funding restrictions
19 included in the annual State budget bill; [and]

20 (xiii) Beginning on January 1, 2019, may provide, subject to the
21 limitations of the State budget, and as permitted by federal law, dental services for adults
22 whose annual household income is at or below 133 percent of the poverty level; AND

23 **(XIV) BEGINNING ON JANUARY 1, 2020, SHALL PROVIDE,**
24 **SUBJECT TO THE LIMITATIONS OF THE STATE BUDGET, AND AS PERMITTED BY**
25 **FEDERAL LAW, SERVICES FOR PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC**
26 **DISORDERS ASSOCIATED WITH STREPTOCOCCAL INFECTIONS AND PEDIATRIC**
27 **ACUTE ONSET NEUROPSYCHIATRIC SYNDROME, INCLUDING THE USE OF**
28 **INTRAVENOUS IMMUNOGLOBULIN THERAPY, FOR ELIGIBLE PROGRAM RECIPIENTS.**

29 **Article – Insurance**

30 15–854.

31 **(A) THIS SECTION APPLIES TO:**

32 **(1) INSURERS AND NONPROFIT HEALTH SERVICE PLANS THAT**
33 **PROVIDE HOSPITAL, MEDICAL, OR SURGICAL BENEFITS TO INDIVIDUALS OR GROUPS**

1 ON AN EXPENSE-INCURRED BASIS UNDER HEALTH INSURANCE POLICIES OR
2 CONTRACTS THAT ARE ISSUED OR DELIVERED IN THE STATE; AND

3 (2) HEALTH MAINTENANCE ORGANIZATIONS THAT PROVIDE
4 HOSPITAL, MEDICAL, OR SURGICAL BENEFITS TO INDIVIDUALS OR GROUPS UNDER
5 CONTRACTS THAT ARE ISSUED OR DELIVERED IN THE STATE.

6 (B) AN ENTITY SUBJECT TO THIS SECTION SHALL PROVIDE COVERAGE FOR
7 MEDICALLY NECESSARY DIAGNOSIS, EVALUATION, AND TREATMENT OF PEDIATRIC
8 AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH
9 STREPTOCOCCAL INFECTIONS AND PEDIATRIC ACUTE ONSET NEUROPSYCHIATRIC
10 SYNDROME, INCLUDING THE USE OF INTRAVENOUS IMMUNOGLOBULIN THERAPY.

11 (C) (1) SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION, THE
12 COVERAGE REQUIRED UNDER THIS SECTION MAY BE SUBJECT TO THE ANNUAL
13 DEDUCTIBLES, COPAYMENTS, OR COINSURANCE REQUIREMENTS IMPOSED BY AN
14 ENTITY SUBJECT TO THIS SECTION FOR SIMILAR COVERAGES UNDER THE SAME
15 HEALTH INSURANCE POLICY OR CONTRACT.

16 (2) THE ANNUAL DEDUCTIBLES, COPAYMENTS, OR COINSURANCE
17 REQUIREMENTS IMPOSED UNDER PARAGRAPH (1) OF THIS SUBSECTION FOR THE
18 COVERAGE REQUIRED UNDER THIS SECTION MAY NOT BE GREATER THAN THE
19 ANNUAL DEDUCTIBLES, COPAYMENTS, OR COINSURANCE REQUIREMENTS IMPOSED
20 BY THE ENTITY FOR SIMILAR COVERAGES.

21 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall apply to all
22 policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or
23 after January 1, 2020.

24 SECTION 3. AND BE IT FURTHER ENACTED, That this Act shall take effect
25 January 1, 2020.